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Highlights 
 Review of clinical phenotypes associated with the dystroglycanopathies 
 Discussion of current animal models and their contribution to 
understanding the disease process 
 New insight into the glycosylation of alpha dystroglycan and the role of 
LARGE 
 Structural information on the LARGE glycan 
 
1. Introduction 
 
The aims of this workshop were to bring together researchers working on the clinical 
and basic aspects of the post-translational modification of dystroglycan, whether in 
relation to the pathophysiology of patients, animal models of dystroglycanopathies, or 
cellular systems addressing the effects of post-translational modification on 
dystroglycan function. By combining clinical and basic scientists, and a range of 
diseases / models / cellular systems, especially with an emphasis on neuroscience, we 
aimed to provide a platform for the sharing of ideas, reagents and animal models, to 
stimulate novel hypotheses and open new avenues of research into these diseases for 
which there are as yet no forms of therapy. With these objectives in mind seventeen 
researchers and clinicians, one patient with limb girdle muscular dystrophy and his 
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partner and one patient representative met in Naarden 27-29 May 2016. Participants 
were from 7 countries (6 UK, 3 USA, 2 Germany, 2 Netherlands, 2 Sweden, 1 France, 
1 Mexico).   
 
2. Background 
 
Dystroglycan is a highly glycosylated extracellular matrix (ECM) receptor that is 
critical for the structure and function of skeletal muscle and the central nervous 
system. The post-translational modification of α-dystroglycan (α-DG) is essential for 
its ability to function as a receptor for laminin G (LG) domain-containing ligands, 
such as laminin, agrin, neurexins, perlecan, pikachurin, and Slit, whereas -
dystroglycan (-DG) is a transmembrane protein that links -DG to any one of a 
number of cytoskeletal adaptor proteins: dystrophin being the most well charactarised 
of these. The dystroglycanopathies describe a group of diseases caused by the loss or 
reduced binding of α-DG to its extracellular ligands. This can be caused by mutations 
in the gene encoding to dystroglycan itself (Dag1), known as primary 
dystroglycanopathies, or the genes encoding for proteins/enzymes that assist with the 
glycosylation of α-DG, so called secondary dystroglycanopathies. Defects in at least 
17 genes fall into this latter category. Recent studies have elucidated the function of 
many of these enzymes and have positioned them in the O-mannosylation 
glycosylation pathway of α-DG. Several advances have been made since the last 
workshop and the overall aim of the present gathering was to discuss these within the 
context of the disease process, advances in knowledge of the functions of 
dystroglycan itself and potential strategies for treatment.  
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3. The spectrum of CMD/LGMD2 (from patient to clinic) 
3.1 A patient’s perspective. 
 
Neil Bevan provided a moving perspective of his life as his disease progressed, which 
included his time at college where he met his future wife Lyndsey, their wedding and 
their hopes and aspirations for their future life together with their eclectic collection 
of animals. His contribution was particularly valued by those participants who never 
come into contact with patients; the overall feeling being that it gave focus to their 
work and would enable them to share this with students. We were all very grateful 
that Neil chose to share so much with us.  
 
3.2 Update on diagnosis of the dystroglycanopathies. 
Natalie Seta (Paris, France) discussed the genes involved in α-DG glycosylation 
which encode for 13 glycosyltransferases (POMT1, POMT2, POMGNT1, FKRP, 
FKTN, B3GALNT2, B4GAT1 (=B3GNT1), LARGE, POMGNT2, TMEM5, DPM3, 
2, 1), 2 kinases (Dol kinase, Protein-O-mannosyl kinase) and 2 enzymes involved in 
nucleotide sugar production (ISPD, GMPPB). She explained that in France diagnosis 
is implemented on the basis of clinical and biological features associated with 
congenital muscle dystrophy, limb girdle muscular dystrophy, lissencephaly, and 
elevated serum CK; a muscle biopsy is used to confirm muscular dystrophy. Using 
antibody IIH6 (which identifies the glycosylated epitope of α-DG), abnormalities can 
be shown either in muscle biopsy or using cultured skin fibroblasts. Currently next 
generation sequencing allows for the testing of all 18 genes in one operation.  When 
no mutation in these genes is revealed, whole exome sequencing is performed, in 
order to identify new related genes. Professor Seta reported that in the last 10 years 
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more than 250 patients were diagnosed in her laboratory: 125 fetal cases, 88 children 
and 39 adults. These diagnosis led to 5-10 prenatal diagnosis a year. POMT1, 
POMT2, POMGNT1, TMEM5, ISPD mutations were present in 2/3 of the fetal cases; 
POMT1, POMT2, POMGNT1, FKRP mutations in 3/4 of the children; FKRP was the 
most common mutated gene in adults. The molecular diagnosis efficiency?? was 85% 
in the fetal cases which was much better than that for children (36%), and adults 
(22%). Finally, she explained that no strong genotype-phenotype correlation was 
evident, with POMT1, POMT2, POMGNT1, FKRP, FKTN, ISPD mutations being 
implicated across the entire clinical spectrum from the most severe to the mildest 
presentation.   
 
3.3  The Myo-Seq project 
Volker Straub discussed the MYO-SEQ project which is based at Newcastle 
University, UK where they apply whole exome sequencing to a large cohort of 
patients with unexplained limb‐girdle weakness. Professor Straub stated that more 
than 500K exomes and 50K genomes of normal healthy individuals. He discussed the 
Care and Trial Site Registry (CTSR) which includes 320 registered sites worldwide. 
Blood and consent are taken in each centre and then DNA is shipped to Newcastle. 
Only known genes are evaluated i.e. those associated with neuromuscular disorders. 
Variants have been identified in 58 of 169 candidate genes which is less than 1%. 
However, it is difficult to determine what mutations are disease causing as for 
example everyone has titin variants – essentially polymorphisms. The most common 
mutations were in calpain,  Ryr1 and dysferlin, POMT2 mutations were more 
common than anticipated. The MYO-SEQ project uses a database called PhenoTips.  
Phenotypic data from 1,100 patient records is contained in myoseq. The average age 
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at recruitment is 39.1 yrs for males and 54 for females. Likely disease causing 
variants have been identified in 214 patients which equates to 42%. This does 
however, vary between centres as it depends on the experience of the clinicians.  The 
aim now is to collect additional clinical data for deep phenotyping, undertake trio 
sequencing and include an additional 1000 samples. 
 
Volker Straub also discussed some interesting clinical findings, namely those relating 
to the POMT2 clinical spectrum which included one patient who was still ambulant at 
52.  He also mentioned that sometimes a deficiency in either dystroglycan or laminin 
was not that evident. Further discussions on MRI data seemed to suggest that the 
tibialis anterior was the best preserved muscle in all the dystroglycanopathies. Pattern 
recognition was discussed and the value of MRI for diagnostics and as an outcome 
measure in clinical trials. Particularly since it is something that can be done on a 
patient at 5 years without anaesthesia. Since the percentage of fat does not change 
with age in normal individuals it would be feasible to quantify fat as a pathological 
readout.  
 
4  The identification of new genes/mutations and biochemical aspects of the 
glycosylation process. 
4.1  Novel mutations at the severe end of the clinical spectrum 
Hans van Bokhoven described the work of his group in identifying known and novel 
mutations at the severe end of the dystroglycanopathy spectrum. They have collected 
DNA and cell lines from patients diagnosed with Walker–Warburg syndrome (WWS) 
or the slightly milder Muscle–Eye–Brain (MEB) phenotype. Using exome sequencing 
the patient data is first analysed for variants in known genes namely DAG1 (primary 
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dystroglycanopathy), POMGnT1, POMGnT2 (GTDC2/C3ORF39), POMT1, POMT2, 
FCMD, FKRP, LARGE1, TMEM5, B3GNT1 (B4GAT1), B3GALNT2, and POMK 
(secondary dystroglycanopathy), and those engaged in combined N- and O-
glycosylation defects DPM1/2/3, DOLK, ISPD, and GMPPB (tertiary 
dystroglycanopathy). In the cohort of 100 families, at least 69 are explained by 
mutations in these genes. This is likely to be an underestimate, as not all genes have 
been fully covered in all families. In addition, the cohort does contain a low 
proportion of families with an atypical phenotype. The question arises as to how 
many other genes are involved in severe-end dystroglycanopathy cases. According to 
the present data there is room for some additional genes, but their identification has to 
rely on genome-wide sequencing efforts.  
All genes known so far have been uncovered by the lassavirus screen presented by 
van Bokhoven [1]. However, besides SLC35A1 this screen has not revealed any other 
obvious candidate genes for dystroglycanopathies. Genetic studies have yielded 
several gene mutations of interest for genotype-phenotype associations. One is a 
family in which a homozygous DAG1 mutation was identified. This highly 
consanguineous family has five individuals with the manifestations of Walker-
Warburg syndrome (WWS). Mutations in DAG1 are rare and so far only four 
missense mutations have been reported that were associated with LGMD with or 
without cognitive impairment and one case with a Muscle-Eye-Brain-Disease-like 
phenotype. The mutation in the present WWS-like family is a frameshift 
c.743C>delC, predicting a premature termination codon p.Ala248Glufs*19 affecting 
the synthesis of both α- and β- dystroglycan. Indeed, Western blot analysis and 
laminin-overlay analysis confirmed the absence of both dystroglycan subunits in 
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patient myoblasts. This is the first report of a full DAG1 loss-of-function allele in 
humans ([2]). The associated phenotype is severe and associated with early lethality.  
Another remarkable observation is the identification of a B3GALNT2 mutation 
associated with a mild phenotype. Diagnostic exome sequencing in two brothers of 14 
and 8 years of age with an unexplained type of intellectual disability identified a 
compound heterozygous mutation in the B3GALNT2 gene (Ile276Leufs*; 
Arg330Cys). The boys presented mild-moderate intellectual disability, speech 
disorder, no structural brain anomalies and no muscular dystrophy. Interestingly, 
another family with a comparable phenotype and a homozygous missense mutation in 
B3GALNT2 was identified by a collaborating group in the UK (Dr. A. Crosby). The 
phenotypes of patients in both families is remarkably mild in comparison to those 
cases previously reported to be caused by mutations in B3GALNT2. Strikingly, the 
differential phenotypes cannot be explained by the residual activity of the mutant 
proteins as a complementation assay with wild type and mutant proteins could not 
identify a relationship between the severity of the phenotype and the capacity to 
restore IIH6-positive glycosylation in B3GALNT2-deficient cells.   
 
4.2 The biochemistry of the dystroglycanopathies 
Dirk Lefeber (Nijmegen, The Netherlands) discussed the tertiary 
dystroglycanopathies which include those genes/proteins that indirectly modify α-DG 
glycosylation.  Glycosylation of proteins requires sufficient availability of nucleotide-
sugars as building blocks. Defects in their levels could also result in deficient O-
mannosylation of α-DG. The first defect identified in this category was DPM3 
deficiency which was shown in an adult patient with LGMD, this was followed by the 
discovery of mutations in DPM2 [3] and DPM1 in young patients with neurological 
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symptoms and skeletal muscle involvement, without overt structural brain defects, 
subsequently GMPPB mutations were identified in patients with LGMD, MEB or 
LGMD with additional myasthenia symptoms. Interestingly, some defects (DOLK 
with dilated cardiomyopathy [4] and SRD5A3 with mainly eye and brain pathology) 
presented in patients with isolated symptoms, indicating the presence of tissue-
specific pathways for α-DG glycosylation. In summary, the synthesis of the dolichol-
P-mannose building block requires 6 different genes. Additionally, many genes are 
involved in the synthesis of glucuronic acid, xylose, N-acetyl-glucosamine, N-acetyl-
galactosamine and ribitol, most of which are not yet associated with disease.  
 
Recent studies [5] uncovered a novel pathway in human sugar metabolism, involving 
synthesis of CDP-ribitol by ISPD (isoprenoid synthase domain containing).  
Subsequent work revealed that CMP-sialic acid transporter SLC35A1 is also required 
for dystroglycan O-mannosylation, independent of sialic acid [6]. Since nucleotide-
sugars are commonly involved in multiple glycosylation pathways, (ISPD is likely to 
be the exception), genetic defects in sugar metabolism result in clinical phenotypes 
that share symptoms with the dystroglycanopathies for example the Congenital 
Disorders of Glycosylation (CDG). Further in analogy with CDG due to deficient 
protein N-glycosylation, it can be speculated that defects in Golgi homeostasis will 
also result in (tissue-specific) abnormal α-DG O-mannosylation. As an example, the 
subunits of the COG complex, known CDG defects, are known to be important for 
normal α- dystroglycan O-mannosylation [7].  
Finally, Dr. Lefeber presented novel methodology for a highly sensitive and specific 
monitoring of sugar metabolites in samples of patients and model systems. This will 
be applied to dissect the tissue-specific mechanisms in sugar metabolism, and to test 
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compounds that are able to restore deficient glycosylation as potential future 
therapeutic strategy. 
 
4.3 Recent findings regarding the posttranslational processing of dystroglycan. 
In the first of a two-part presentation Kevin Campbell reviewed the novel post-
translational processing that is required for dystroglycan function. Ligand binding by 
α-DG is reduced when O-glycosylation is perturbed.  Recent genetic data shows that 
mutations in at least 18 genes encoding known and putative glycosyltransferases 
disrupt the O-glycosylation of α-DG and cause muscular dystrophy.  His previous 
efforts to understand the molecular mechanism underlying dystroglycan’s ability to 
bind the extracellular matrix had led to the identification of a novel phosphorylated O-
mannosyl trisaccharide (N-acetylgalactosamine-β3-N-acetylglucosamine-β4-
mannose) on α-DG.  In this presentation he showed that three of the newly identified 
proteins (GTDC2, B3GALNT2, and SGK196) are involved in synthesizing the 
phosphorylated trisaccharide. Interestingly, SGK196 phosphorylates the 6-position of 
O-mannose, using ATP as the donor, and the addition of this phosphate residue is a 
prerequisite for formation of the ligand-binding motif.  The SGK196-mediated 
phosphorylation occurs only when the GalNAc-β3-GlcNAc-β-terminus is linked to 
the 4-position of O-mannose, indicating that this disaccharide serves as the substrate 
recognition motif for SGK196.  
Kevin Campbell also described LARGE1 as a bifunctional enzyme that has both 
xylosyltransferase (Xyl-T) and glucuronyltransferase (GlcA-T) activities, and showed 
that it generates the novel heteropolysaccharide [-GlcA-β1,3-Xyl-α1,3-]n, which has 
now been termed “matriglycan”.  He confirmed that this polysaccharide structure is 
present in native tissues, identifying two exoglycosidases that collectively can 
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hydrolyze glycans on native α-DG: β-glucuronidase (Bgus) from T. maritima, and α-
xylosidase (Xylsa) from S. solfataricus. He first tested these enzymes with a 
chemically defined substrate, the LARGE-synthesized pentasaccharide G5. 
Alternating treatment of G5 with the two enzymes removed one sugar at a time from 
the nonreducing end, demonstrating that Bgus and Xylsa cleave β-linked GlcA and α-
linked Xyl, respectively, without measurable endoglycosidase activity.  Finally, he 
demonstrated that simultaneous treatment of rabbit skeletal muscle α-DG with Bgus 
and Xylsa dramatically reduced the apparent molecular mass of α-DG, as assessed by 
SDS-PAGE, and abolished reactivity with the matriglycan-specific antibody IIH6, 
whereas treatment of α-DG with either exoglycosidase alone had no such effect. 
Similar results were obtained with mouse skeletal muscle α-DG: wild-type mouse α-
DG treated with both Bgus and Xylsa migrated similarly to α-DG from Largemyd 
mice, which have an inactivating mutation in the Large1 gene; this protein also failed 
to react with matriglycan-specific antibodies IIH6 and VIA41, as well as with 
laminin. Overall, Kevin Campbell’s results demonstrate that native α-DG in skeletal 
muscle of rabbit and mouse is modified with multiple [-GlcA-β1,3-Xyl-α1,3-] repeats, 
and that this modification is required for α-DG to bind laminin.  
  
5. Animal Models of the dystroglycanopathies. 
5.1  Insight into the disease process using mouse models. 
Sue Brown (London, UK) Mutations in the FKRP gene cause a wide range of 
clinical phenotypes in the human. In this presentation the various mouse models used 
for investigating the disease process were discussed and summarised. Focusing on the 
structural brain defects of the mouse with the global reduction in Fkrp, Dr. Brown 
discussed the early disorganisation evident in the neuroepithelium, and the 
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mislocalisation of the Cajal Retzius cells which appears to correlate with later defects 
in the pial basement membrane.  She also discussed analyses using new monoclonal 
antibodies to the core dystroglycan protein generated by Glenn Morris’ lab which 
showed some interesting differences with respect to staining of the tongue compared 
to the LARGEmyd and POMGnT1null mice.  Further discussions centred on the 
correlation between IIH6 and Fkrp expression during embryonic/fetal development in 
a mouse in which FKRP expression is reported by EGFP. Finally in the FKRPMD  
mouse in which there is a restoration of Fkrp in the central nervous system (via the 
expression of Cre recombinase under control of the Sox1 promoter), it was shown that 
there was increased levels of α-DG glycosylation and laminin α2 expression relative 
to the global knock down (FKRP
KD
) which influences the separation of secondary 
myotubes from the parent primary myotube during the second half of gestation.  
 
5.2  The expression of functional α-DG in dystroglycanopathy models. 
Qi Lu, (Carolinas Medical Center, Charlotte NC, USA) reported that a small 
number of fibres expressing functional α-DG at up to normal levels is a general 
feature of diseased muscles in patients with FKRP mutations.  These fibres are often 
marked with the expression of embryonic myosin heavy chain suggesting that the 
expression of functional α-DG is related to muscle regeneration. These “revertant” 
fibers were also observed in mouse models bearing fkrp P448LNeo- mutations and a 
severe phenotype. This line expresses relatively normal levels of the P448L mutant 
transcript. Lu’s lab confirmed the association of functional α-DG expression with 
muscle regeneration by notexin and cationic polymers induced degeneration and 
regeneration. No revertant fibers were detected in either LARGEmyd mice or FKRP 
P448LNeo+ mutant mice which express significantly reduced levels of mutant FKRP 
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transcript.  These results suggest that the expression of functional α-DG is dependent 
on LARGE and FKRP. Nonetheless mutant FKRP carrying the P448L mutation is 
sufficient for inducing normal levels of functional α-DG in regenerating fibers. Qi Lu 
further showed that muscle fibres of the P448LNeo- mutant mice express near normal 
levels of functional α-DG in skeletal muscle during the first postnatal week. 
Importantly, expression, although at much lower levels than in skeletal muscles, is 
also detected in the cardiac muscle. This postnatal expression remains FKRP and 
LARGE dependent. These results suggest that modulation of FKRP expression or 
other factors could be explored in future experimental therapies. Interestingly, 
enhanced expression of functional α-DG is observed in muscles of the mutant 
fkrpP448LNeo- mouse models after steroid treatment. Qi Lu’s studies with gene 
delivery also showed that overexpression of P448L mutant FKRP is able to rescue the 
glycosylation defect of α-DG and prevent disease progression in the FKRP mutant 
mice, strongly suggesting that mutant P448L FKRP retains much of its biological 
activity with regard to the glycosylation of α-DG. These data provide the rationale for 
interventions that either enhance the expression of endogenous mutant FKRP or 
modulate the glycosylation pathways for achieving therapeutic restoration of 
functional α-DG.      
 
5.3  What can other models tell us about the pathogenesis? 
Halyna Shcherbata presented her initial characterization of the Dystrophin-
Glycoprotein Complex (DGC) in Drosophila. This complex appears to perform 
similar functions in the muscle and nervous system of Drosophila as their homologs 
in humans. Abnormalities in the Drosophila include age-dependent muscle 
degeneration, reduced mobility, hyperthermic seizures, a shorter life span, 
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myotendinous junction and brain development defects [8-12]. Shcherbata’s lab took 
advantage of the genetic tractability of Drosophila to search for novel DGC-
interacting components, as well as factors involved in its signaling and regulation, 
including miRNAs. This work showed similarities in miRNA profiles under either 
stress or dystrophic conditions, indicating that mutations in DGC-linked proteins are 
associated with an entourage of regulatory and homeostatic anomalies [13]. 
Importantly, the expression of multiple miRNAs, including those which are stress-
sensitive, directly depend on the DGC-NOS-HDAC signaling pathway [13, 14]. This 
suggests that future in depth analysis of DGC interacting proteins and their regulatory 
miRNAs will promote a better understanding of DGC signaling and regulation and 
facilitate the development of alternative therapeutic pathways for neuromuscular 
disorders using miRNAs. 
Dystroglycan (Dg) is subjected to miRNA regulation the mode of which differs 
depending on the developmental stage and the cell type. During embryonic 
development, Dg is targeted in an expression-tuning mode, i.e. the miRNA 
determines the mean of the target gene expression, resulting in an “on-off“ expression 
pattern [12]. The highly evolutionary conserved miR-9a acts as the canalization factor 
in the dynamic process of muscle attachment establishment and protects tendon 
precursors from noisy expression of Dg and other critical muscle differentiation 
genes. Other identified miRNAs that target Dg are the mir-310s, these act in an 
expression-buffering mode i.e. when a miRNA and its target are co-expressed and the 
miRNA decreases the variance of the target [14]. This operates via a perceptive-
executive mechanism; namely expression of miR-310 is induced by high levels of Dg 
which can target only a portion of Dg mRNAs with an extended 3’UTR thereby 
preventing Dg levels from being reduced below a certain threshold. This regulation is 
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of great importance in the developing nervous system to keep the equilibrium of Dg 
expression. In the CNS, aberrant (too high and too low) Dg levels affect neuronal 
stem cell division, while higher levels accelerate proliferation and perturb neuron 
differentiation, causing formation of cobblestone-like structures that outgrow the 
normal contour of the extracellular matrix defined brain. This phenotype is similar to 
the cortical abnormalities associated with the dystroglycanopathies in humans, 
implying that Drosophila Dg mutants can serve as a model for cobblestone 
lissencephaly [14]. Deregulation of Dg affects the distribution of major cell adhesion 
proteins, presumably affecting the ECM composition, and consequently resulting in 
abnormal tissue assembly [15]. Thus, fine-tuning of Dg expression by miRNAs in the 
nervous tissue is key in the regulation of neuronal development, plasticity, and 
maintenance. 
 
6 Aspects of dystroglycan cell biology, iPS cells, nuclear dystroglycan and DG 
proteolysis 
 
6.1  New cellular models for the dystroglycanopathies 
Yung-Yao Lin (London UK) presented on CRISPR-mediated genome editing in 
human induced pluripotent stem cells for modelling FKRP-deficient 
dystroglycanopathy. Patient-specific induced pluripotent stem cells (iPSC) have been 
differentiated down a neural lineage cells to investigate pathological mechanisms 
underlying the CNS involvement. Nevertheless, one major challenge is the lack of an 
appropriate isogenic control, which minimizes the variability between different 
genetic backgrounds. Yung-Yao Lin has therefore developed a protocol to carry out 
targeted gene correction in patient-specific FKRP-iPSC and targeted gene mutation in 
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wildtype iPSC using CRISPR/Cas9-mediated genome editing technology. 
CRISPR/Cas9 induced homologous recombination was used in combination with the 
piggyBac positive/negative selection cassette, which allows precise modification of 
the mammalian genome at single base-pair levels without leaving footprints. Targeted 
gene correction of FKRP was shown to restore α-DG functional glycosylation in 
iPSC-derived neurons, whereas a targeted mutation of FKRP disrupts α-DG 
glycosylation. In the future isogenic pairs of human iPSC-derived cellular models will 
further elucidate mechanisms underlying the CNS involvement and muscle pathology 
due to FKRP deficiency. Moreover, these unique cellular models will be exploited to 
facilitate the discovery of therapeutic targets in FKRP-deficient muscular dystrophies. 
 
6.2  Does dystroglycan have a role at the nuclear envelope? 
Bulmaro Cisneros (CINVESTAV, Mexico) reported that β-dystroglycan has the 
ability to target to, and conform specific protein assemblies at the plasma membrane 
and nuclear envelope (NE). However, molecular mechanisms controlling the 
subcellular fate and abundance of β-DG in each compartment, as well as the 
physiological consequences of a failure in its intracellular trafficking pathway are 
largely unknown. Dr. Cisneros Vega presented data showing that β-DG is a 
nucleocytoplasmic shuttling protein with a functional nuclear export pathway that 
depends on the recognition of a nuclear export signal located in the transmembrane 
domain of β-dystroglycan (763ILLIAGIIAM772) by exportin CRM1. He further 
showed that altered nuclear export of β-dystroglycan is involved in the development 
of nucleolar stress in Hutchinson-Gilford progeria syndrome cells, thus further 
demonstrating the importance and biological significance of controlling the 
physiological overall levels of -DG as well as the nuclear levels β-dystroglycan.   
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6.3 The role of dystroglycan in postnatal brain development. 
Holly Colognato presented work which showed that dystroglycan is critical for brain 
development, indeed the dystroglycanopathies can result in profound deficits in brain 
structure and function. In the developing brain, dystroglycan is found on the basal 
endfeet of embryonic radial glia [16] and the loss of radial glial attachment to the pial 
basement membrane is thought to underlie neuronal migration defects in these 
dystroglycanopathies [17]. In the adult brain, dystroglycan is found on the 
perivascular endfeet of astrocytes, where it mediates their adhesion to the vascular 
basal lamina at the blood-brain barrier and regulates Kir4.1 and aquaporin-4 
localization. However, there is limited understanding of dystroglycan’s function in the 
developing postnatal brain.  
Extracellular matrix, including the dystroglycan ligand, laminin, has been reported to 
regulate neural stem cell quiescence in the subventricular zone (SVZ) of the adult 
brain. However the function of extracellular matrix and its receptors in the developing 
SVZ remains unknown. Holly Colognato discussed a new study in which her lab 
found that dystroglycan regulates a unique developmental restructuring of 
extracellular matrix in the early postnatal SVZ. Dystroglycan is furthermore required 
for ependymal cell differentiation and assembly of niche pinwheel structures, at least 
in part by suppressing Notch activation in radial glial cells, which leads to the 
increased expression of MCI, Myb, and FoxJ1, transcriptional regulators necessary for 
acquisition of the multiciliated phenotype. Dystroglycan also regulates perinatal radial 
glial cell proliferation and transition into intermediate gliogenic progenitors, such that 
either acute or constitutive dystroglycan loss-of-function results in increased 
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oligodendrogenesis. These findings reveal a role for dystroglycan in orchestrating 
both the assembly and function of the SVZ neural stem cell niche. 
 
7 Understanding the laminin binding, interface/functional consequences how 
they relate to different tissues/developmental regulation. How can we move 
forward what models would be useful/what techniques? 
 
7.1 Structural studies of the LARGE glycan. 
Erhard Hohenester (London UK) and Kevin Campbell (Iowa, USA) have 
determined a crystal structure of laminin G-like (LG) domains 4-5 of laminin α2 
bound to a LARGE-synthesized oligosaccharide. Their results provide the first 
atomic-resolution insight into the laminin-α-DG interaction that is compromised in a 
number of congenital muscular dystrophies. The crystal structure shows that a single 
glucuronic acid-β1,3-xylose disaccharide unit of the LARGE glycan straddles a Ca2+ 
ion in the LG4 domain, with oxygen atoms from both sugars replacing Ca
2+
-bound 
water molecules. The chelating binding mode explains the high affinity of this 
protein-carbohydrate interaction, which was determined by using NMR.  Specificity 
for the LARGE glycan is achieved by steric exclusion of C5-substituted sugars from 
the xylose subsite. The binding mode of the LARGE glycan is predicted to be 
conserved in all other LG domains, and is consistent with prior mutagenesis results of 
neurexin domains LG2 and LG6. 
 
7.2  Adhesion complexes in muscle 
Mutations in the LAMA2 gene encoding the α-2 chain of laminin-211 cause 
congenital muscular dystrophy (MDC1A). Laminin-211 chain binds two major cell 
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surface on the muscle cell surface namely dystroglycan, which is part of the 
dystrophin-glycoprotein complex, and integrin α7β1. Absence of laminin α2 chain 
does not affect the expression of the dystrophin-glycoprotein complex but leads to a 
secondary reduction of integrin α7 chain at the sarcolemma. In order to establish the 
relationship between laminin α2 chain and members of the dystrophin-glycoprotein 
complex and integrin α7, respectively, Madeleine Durbeej and co-workers generated 
three new mouse models. Mice deficient in either laminin α2 chain and dystrophin 
(dy3K/mdx) or laminin α2 chain and α-sarcoglycan (dy3K/Sgcb), display extremely 
severe muscular dystrophy, with massive muscle degeneration, inflammation and 
fibrosis. Mice devoid of laminin α2 chain and integrin α7, on the other hand, do not 
display an aggravated phenotype compared to single laminin α2 chain knock-out 
mice. These data suggest that laminin α2 chain and members of the dystrophin-
glycoprotein complex have overlapping but non-redundant functions despite being 
part of the same adhesion complex. In contrast, laminin α2 chain and integrin α7β1 
have very similar roles in muscle.  
More recently, the Durbeej group has performed comparative proteomic analyses of 
affected muscles from dy3K/dy3K mice in order to obtain new insights into the 
molecular mechanisms underlying MDC1A. A large number of differentially 
expressed proteins in diseased compared to normal muscles were identified. A 
majority of the dysregulated proteins were involved in different metabolic processes 
and mitochondrial metabolism. These data imply that metabolic alterations could be 
novel mechanisms that underlie MDC1A and might be targets that should be explored 
for therapy. Indeed, preliminary data indicate defective metabolism in laminin α2 
chain-deficient muscle cells and this new disease driving mechanism can be targeted 
with good results in mice. 
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7.3  New insight into LARGE2 and its substrates 
LARGE2 is a homolog of LARGE1, and both are bifunctional glycosyltransferases 
that elaborate a Xyl-GlcA disaccharide repeat on α-DG. This disaccharide repeat 
forms the functional binding glycan that links α-DG at the cell surface to laminin G 
domain-containing proteins in the extracellular matrix. Kevin Campbell showed that 
LARGE2 can extend a IIH6 reactive (laminin-binding) glycan on ES cells that are 
deficient for α-DG or the ability to transfer O-mannose or ribitol 5-phosphate, 
indicating that functional glycans exist independent of α-DG. He identified glypican-4 
and other proteoglycans (i.e. biglycan, syndecans) as endogenous substrates for 
LARGE2 in vitro and in the kidney, using biochemical and mass spectrometry 
methods. These findings reveal that LARGE2 has activity toward both heparan 
sulfate- and chondroitin/dermatan sulfate-containing proteoglycans. 
 
8. Omics: the search for new mutations, biomarkers and post translational 
modifications. 
8.1  Biomarkers  
Sebahattin Cirak presented clinical data of 48 patients, largely recruited in 
collaboration with Haluk Topaloglu. The inclusion criteria was based upon clinical 
phenotype, high CK, brain and eye involvement together with a deficiency of α-DG 
on muscle biopsy.  Forty-eight patients, including 4 affected siblings, from 44 
families with α-DGpathy were included in the study, 83% of the cases are solved and 
17% remain unsolved. Molecular work-up included whole exome sequencing 
including Copy Number Variation analysis. The mean age of the patients (27 boys, 21 
girls) were approximately 6.4 years (6 months-19 years). Consanguinity was present 
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in 24 families, and 9% (n=4) had an affected sibling. MRI was available in 33 patients 
(69%), and 28 (84.8%) had abnormal findings. Homozygous or compound 
heterozygous mutations in α-DGpathy genes were detected in 83% probands. 
Mutations in POMT2 were the most prevalent (n=9) in our cohort, followed by 
POMT1 (n=7) and POMGNT1 (n=7), TMEM5 (n=2), FKRP (n=4), FKTN (n=2), 
GMPPB (n=2), ISPD (n=2), POMK (n=2), B3GNT1 (n=1) and LAMA2 (n=2). 
Interestingly, two of our cases were patients with a mutation in LAMA2 and one case 
identified as a double trouble mutation in FKRP and SEPN1 with a congenital 
muscular dystrophy phenotype.  
FKRP mutations were frequently associated with cerebellar cysts although a larger 
study would be needed to confirm statistical significance. Muscle eye brain patients 
often displayed spasticity of the lower limbs.  Importantly, we reported a patient with 
LGMD and congenital mirror movements, with a novel homozygous missense 
mutation in POMK (exon 5, c.401T>G, p.V134G). A 17-year-old right-handed boy 
who presented with childhood onset muscle weakness, easy fatigue, clumsiness, and 
difficulty in running and climbing. Remarkably, physical examination at 19 years 
revealed mirror movements in the upper limbs indicating a defect in axon guidance. 
To date, mirror movement have been reported in only one patient with αDGpathy 
which was due to LARGE mutation [23]. Our etiological yield with exome 
sequencing has been 83 % so far. 
 
With regard to clinical endpoints/biomarkers Sebahattin Cirak discussed a pilot 
biomarker study undertaken in collaboration with the Wellstone Muscle Center in 
Iowa. Dr. Mathews provided 22 anonymous LGMD2I serum samples from subjects 
between 6 and 49 years to analyze potential serum biomarkers that were identified in 
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DMD mouse models and in boys with DMD [19]. In preliminary work, in 
collaboration with Yethrib Hathout Dr. Cirak used label free mass spectrometry to 
identify the target proteins. Preliminary Results are shown in Table 1 and validation 
of these markers in longitudinal studies is in progress.  
MMP9 was also discussed since an increase of MMP9 was observed with age in 
control serum which was not observed in control plasma samples. This suggests that 
MMP9 serum levels might be age related rather than related to disease progression 
and is remarkable since MMP9 has been investigated as potential biomarker in other 
muscular dystrophies. Furthermore, it has been debated that MMP9 is increased with 
the activation of thrombocytes and the clotting cascade [20] and MMP9 is known to 
be involved in the proteolysis of -DG.  
 
Sebahattin Cirak also reported that he has isolated total RNA from LGMD2I serum 
samples and quantified 800 known human miRNA with the NanoString technology 
which allows absolute quantification. A heatmap of 12 miRNAs has been constructed 
showing a convincing clustering depending on the age of LGMD2I patients. Further 
biomarkers studies including innovative novel technologies for protein and miRNA 
quantification from urinary exosomes and plasma is in progress. 
 
8.3  Dystroglycan phosphorylation 
Steve Winder (Sheffield, UK) reported that by studying the fate of the dystrophin 
glycoprotein complex in Duchenne muscular dystrophy (DMD) he has identified 
tyrosine phosphorylation of dystroglycan, the key transmembrane laminin receptor, as 
central to the loss of the entire DGC from the sarcolemma. Preventing 
phosphorylation of dystroglycan in mdx mice by mutation of a key tyrosine 
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phosphorylation site ameliorates the dystrophic phenotype ([21]). Studies in mouse 
myoblasts also demonstrate that pharmacological treatment with proteasome or 
tyrosine kinase inhibitors can increase levels of non-phosphorylated dystroglycan. 
Furthermore by inhibiting tyrosine phosphorylation, ubiquitination or proteasomal 
degradation pharmacologically he demonstrated a reduction in dystroglycan 
phosphorylation and a rescue of the dystrophic phenotype in sapje zebrafish, a fish 
model of DMD. Through the use of FDA approved cancer therapeutics, he showed a 
significant improvement in sapje zebrafish swimming ability when treated with either 
proteasome inhibitors or tyrosine kinase inhibitors such as dasatinib ([22]). These 
studies have now been extended into mdx mice and again certain drug regimen 
demonstrate improvements in muscle pathophysiology including muscle central 
nucleation, serum creatine kinase levels, restoration of dystroglycan and sarcoglycan 
to the sarcolemma and in physical parameters such as wire hanging times.  
These studies demonstrate the utility of inhibiting dystroglycan tyrosine 
phosphorylation as a therapeutic strategy for DMD, particularly as several of the 
compounds that are effective are in existing clinical use. Although this strategy was 
initially focused on identifying new therapeutic strategies to treat DMD, the fact that 
the net result of preventing dystroglycan phosphorylation on tyrosine is to stabilize it 
in the sarcolemma may be of benefit in the dystroglycanopathies.  Reduction in alpha 
dystroglycan binding to laminin in the dystroglycanopathies could perturb outside in 
signaling from the extracellular matrix and lead to aberrant intracellular signaling that 
could also affect dystroglycan stability. Blocking this signaling pathway by inhibiting 
tyrosine phosphorylation may serve to stabilise alpha- and beta-dystroglycan at the 
sarcolemma and preserve the function of α-DG albeit with a reduced laminin binding 
capacity as exemplified in the dystroglycanopathies.  
Page 22 of 31
23 
 
 
9.   A parents perspective on caring and potential treatment strategies. 
Monika Liljedahl (mother of a boy with Limb Girdle Muscular Dystrophy and 
representative for Cure CMD) described how her son and his brother were IVF babies 
of parents 40 years of age. The pregnancy was uncomplicated and they were born at 8 
month by C section. A developmental delay was noted already within the first 6 
weeks of birth with difficulties holding up the head. Her affected son could not sit up 
and keep up with his brother. At 7 months weak reflexes were noticed. At 14 months 
a blood test showed a CPK of 5000, a muscle biopsy taken at 18 months showed 
muscular dystrophy, but no more specific diagnosis could be given. He could walk at 
2.5 years, and carried on until 10 years of age. However, he has never been able to 
skip or run, and has only raised himself up from the floor a few times. He is very 
healthy apart from his muscle weakness, and is intellectually normal.  Sequencing for 
the FKRP gene at 3 years of age showed that he is a compound heterozygote for two 
mutations in the FKRP gene. As a parent Monika set up a screen using skin 
fibroblasts to identify compounds that might up-regulate glycosylated α-DG and 
increase laminin binding. About 100, 000 compounds have so far been screened, these 
are mostly marketed drugs and natural compounds. The best hits have been HDAC 
inhibitors. The boy does various physical therapies that are helpful and the family 
strives for a normal life by engaging the boy in many spare time activities such as 
skiing, sailing and hiking. He is very intellectual, has many friends and enjoys 
computer games. He has a service dog that always stays at his side and which he finds 
very beneficial. 
 
10. Conclusions. 
Page 23 of 31
24 
 
The aims of this workshop were to bring together researchers working on the clinical 
and basic science aspects of dystroglycan glycosylation, whether in relation to the 
pathophysiology of patients, animal models of dystroglycanopathies, or cellular 
systems addressing the effects of these modification on dystroglycan function. A 
number of clinicans and scientists with an interest in different aspects of the 
dystroglycanopathies reviewed a broad range of topics, from patient registries and 
clinical diagnostic approaches to the functional role of dystroglycan in muscle and 
brain, as well as potential new therapeutic approaches to treat this group of diseases. 
We also benefited from presentations from a patient and a parent providing us with 
insight into what it is like to live with LGMD2I.  
DNA sequencing technology has transformed the diagnosis of the 
dystroglycanopathies and this information is being collected in registries in order to 
facilitate the implementation of clinical trials if and when viable therapeutic 
approaches become available. With a doubling since the previous workshop ([23]) in 
the number of identified genes directly responsible for the full function of 
dystroglycan, much discussion centred around how these genes contribute to the way 
that dystroglycan performs its role in muscle and brain, as well as other tissues and 
cells where dystroglycan is also present. Presentations also covered potential 
treatments for the dystroglycanopathies which have so far been tested in mice with 
similar disease symptoms. This ranged from simple small molecule inhibitor drugs to 
alleviate symptoms, to more complicated gene replacement therapies using viruses to 
get new genes into muscle. 
The following key conclusions were reached. 
Page 24 of 31
25 
 
1. An agreement from those present to form a consortium to address future major 
scientific funding programmes that may be announced by National or International 
agencies, such as the EU Horizon 2020 project 
2. A consensus for the naming of  dystroglycanopathies which should be 
classified as Primary Dystroglycanopathies (affecting the dystroglycan gene directly) 
the Secondary Dystroglycanopathies (affecting genes that directly modify 
dystroglycan) and Tertiary Dystroglycanopathies (mutations in genes that indirectly 
affect dystroglycan function). This recommendation will be taken forward to a 
forthcoming ENMC Workshop that will specifically address naming and 
nomenclature of LGMD which also encompasses several dystroglycanopathies. 
3. To share important research reagents and tools such as antibodies, cells, 
tissues and mice through existing biobanks, and to encourage the sharing of 
therapeutic viruses.  
4. Agreement to apply for funding to hold another meeting in 4 years time. 
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Table 1: Candidate Biomarker Analysis in LGMD2I 
DMD protein candidates Locus 
Average 
LGMD2I 
STDEV 
Control
s 
LGMD/Control
s 
Myofibrillar proteins           
Myomesin-3 MYOM3 8.01 6.22 0 Not in controls 
Filamin-C FLNC 7.35 1.88 0 Not in controls 
Titin TITIN 2.48 3.51 0 Not in controls 
Glycolitic enzymes           
Glycogen phosphorylase, 
muscle  PYGM 21.85 13.36 0 Not in controls 
Fructose-bisphosphate 
aldolase A ALDOA 12.18 3.2 4.75 2.56 
L-lactate dehydrogenase 
A chain LDHA 1.86 2.63 3.18 0.59 
Other Muscle specific 
proteins           
Creatine kinase M-type KCRM 13.48 3.74 3.51 3.84 
Myoglobin MYG 2.44 0.05 0 Not in controls 
Extracellular matrix 
protein           
Tenascin TENA 4.29 0.95 1.31 3.28 
Other proteins           
Apolipoprotein(a) APOA 14.72 5.49 6.09 2.42 
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